The preferred radiotherapeutic approach for central (CLT) and ultracentral (UCLT) lung tumors is unclear. We assessed the toxicity and outcomes of patients with CLT and UCLT who underwent definitive five-fraction stereotactic body radiation therapy (SBRT). We reviewed the charts of patients with either CLT or UCLT managed with SBRT from June 2010–April 2019. CLT were defined as gross tumor volume (GTV) within 2 cm of either the proximal bronchial tree, trachea, mediastinum, aorta, or spinal cord. UCLT were defined as GTV abutting any of these structures. Propensity score matching was performed for gender, performance status, and history of prior lung cancer. Within this cohort of 83 patients, 43 (51.8%) patients had UCLT. The median patient age was 73.1 years with a median follow up of 29.9 months. The two most common dose fractionation schemes were 5000 cGy (44.6%) and 5500 cGy (42.2%) in five fractions. Multivariate analysis revealed UCLT to be associated with worse overall survival (OS) (HR = 1.9, p = 0.02) but not time to progression (TTP). Using propensity score match pairing, UCLT correlated with reduced non-cancer associated survival (p = 0.049) and OS (p = 0.03), but not TTP. Within the matched cohort, dosimetric study found exceeding a D4cc of 18 Gy to either the proximal bronchus (HR = 3.9, p = 0.007) or trachea (HR = 4.0, p = 0.02) was correlated with worse non-cancer associated survival. In patients undergoing five fraction SBRT, UCLT location was associated with worse non-cancer associated survival and OS, which could be secondary to excessive D4cc dose to the proximal airways.

Standard therapy for stage III non-small cell lung cancer with chemotherapy and conventional radiation has suboptimal outcomes. We hypothesized that a combination of surgery followed by stereotactic body radiation therapy (SBRT) would be a safe alternative. Patients with stage IIIA (multistation N2) or IIIB non-small cell lung cancer were enrolled from March 2013 to December 2015. The protocol included transcervical extended mediastinal lymphadenectomy (TEMLA) followed by surgical resection, 10 Gy SBRT directed to the involved mediastinum/hilar stations and/or positive surgical margins, and adjuvant systemic therapy. Patients not suitable for anatomic lung resection were treated with 30 Gy to the primary tumor. The primary efficacy end-point was the proportion of patients with grade 3 or higher adverse events (AE) or toxicities. Of 10 patients, 7 patients underwent neoadjuvant chemotherapy. All patients had TEMLA. Nine of 10 patients underwent surgical resection. The remaining patient had an unresectable tumor and received 30 Gy SBRT to the primary lesion. All patients had post-operative SBRT. Median follow-up was 18 months. There were no perioperative mortalities. Six patients had any grade 3 AEs with no grade 4–5 AEs. Of these, 4 were not attributable to radiation. Pulmonary-related grade 3 AEs were experienced by 2 patients. There were no failures within the 10 Gy volume. Overall survival and progression-free survival rates at 2 years were 68% (90% CI 36–86) and 40% (90% CI 16–63), respectively. In carefully selected patients with locally advanced non-small cell lung cancer, combining surgery with SBRT was well tolerated with no local failure. ClinicalTrials.gov identifying number NCT01781741 . Registered February 1, 2013.

This is a case of a woman with massive hemoptysis, associated with a pulmonary artery pseudoaneurysm, and a fistula between the right pulmonary artery and bronchus intermedius. Bronchoscopic evaluation revealed an endobronchial mass in the right bronchus intermedius, suspicious for a tumor. Upon biopsy of the mass, massive bleeding occurred. The right lung was surgically resected. No specific etiology for the fistula was identified on pathologic examination. To our knowledge, this is the first report of a pulmonary artery-bronchial fistula presenting without typically known predisposing factors.

A 69-year-old man with presumed solid gastric mass determined by computed tomography, endoscopic ultrasonography, and fine-needle aspiration underwent videoscopic excision of what resulted in a cystic structure consistent with intra-abdominal esophageal duplication cyst. Esophageal duplication cysts are rare congenital lesions that are difficult to diagnose. They seldom occur entirely below the diaphragm, and occurrence in adults is unusual. Only six such cases are reported in the literature. When diagnosis is made, treatment decisions are not always straight forward, although excision is frequently pursued. The current case describes this unique finding and presents laparoscopic excision as a safe treatment alternative.

Robotic technology is the next iteration of minimally invasive surgery (MIS), with theoretical advantages over conventional thoracoscopic and laparoscopic techniques. These include enhanced visualization, improved dexterity, and superior ergonomics, at the expense of increased costs and operative time and loss of haptics. We critically evaluate robotic surgery outcomes in lobectomy, mediastinal surgery, and esophageal surgery both benign and malignant. We demonstrate that while robotics has performed favorably compared to open surgery, it has been difficult to consistently identify superiority in outcomes over VATS/laparoscopy. However, in certain outcomes and situations, robotics has demonstrated an advantage in the literature. This includes decreased length of stay and complication rates in lobectomy, decreased esophageal perforation rates in Heller myotomy, and improved lymphadenectomy in esophagectomy and lobectomy.